Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 11/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2062372 | 0.94 | KCNA5 (0.38) | KCNA5KCNH2ALOX5APRPS6KB1DPP4 | |
| SCHEMBL2062500 | 0.92 | KCNA5 (0.39) | KCNA5KCNH2ALOX5AP | |
| SCHEMBL885452 | 0.89 | RPS6KB1 (0.38) | KCNA5KCNH2RPS6KB1 | |
| SCHEMBL886322 | 0.88 | KCNA5 (0.39) | KCNA5KCNH2GRM5 | |
| SCHEMBL886532 | 0.88 | KCNA5 (0.36) | KCNA5KCNH2ALOX5APRPS6KB1 | |
| SCHEMBL885844 | 0.85 | KCNA5 (0.42) | KCNA5KCNH2ALOX5AP | |
| SCHEMBL885978 | 0.85 | KCNA5 (0.42) | KCNA5KCNH2 | |
| SCHEMBL885665 | 0.85 | KCNA5 (0.42) | KCNA5KCNH2 | |
| SCHEMBL885962 | 0.85 | KCNA5 (0.50) | KCNA5KCNH2GRM5 | |
| SCHEMBL884813 | 0.84 | KCNA5 (0.43) | KCNA5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233897-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | claimed |
| EP-1940406-A2 | POTASSIUM CHANNEL INHIBITORS | Merck and Co., Inc. (US) | 2008-07-09 | — | — | EP | claimed |
| WO-2007050348-A2 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2007-05-03 | — | — | WO | claimed |
| US-8148535-B2 | Potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090233897-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233897-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | KCNA5 11/4885KCNH2 3/4885ALOX5AP 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.